|
"tsou h h"的相关文件
显示项目 51-60 / 64 (共7页)
<< < 1 2 3 4 5 6 7 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2020 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T.; Tsou H.-H.; CHIUN HSU; Yen C.-J.; Yang S.-H.; Chen M.-H.; Chiang N.-J. |
| 國立成功大學 |
2020 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang, N.-J.;Chen, M.-H.;Yang, S.-H.;Hsu, C.;Yen, C.-J.;Tsou, H.-H.;Su, Y.-Y.;Chen, J.-S.;Shan, Y.-S.;Chen, L.-T. |
| 臺大學術典藏 |
2018-09-10T08:37:09Z |
A consistency approach to evaluation of bridging studies and multi-regional trials
|
Tsou, H.-H.;Chien, T.-Y.;Liu, J.-P.;Hsiao, C.-F.; Tsou, H.-H.; Chien, T.-Y.; Liu, J.-P.; Hsiao, C.-F.; JEN-PEI LIU |
| 臺大學術典藏 |
2018-09-10T08:10:20Z |
Sample size determination for a specific region in a multiregional trial
|
Ko, F.-S.;Tsou, H.-H.;Liu, J.-P.;Hsiao, C.-F.; Ko, F.-S.; Tsou, H.-H.; Liu, J.-P.; Hsiao, C.-F.; JEN-PEI LIU |
| 臺大學術典藏 |
2018-09-10T06:24:51Z |
Use of prior information for Bayesian evaluation of bridging studies
|
|JEN-PEI LIU; Hsiao, C.-F.;Hsu, Y.-Y.;Tsou, H.-H.;Liu, J.-P.; Hsiao, C.-F.; Hsu, Y.-Y.; Tsou, H.-H.; Liu, J.-P. |
| 國立成功大學 |
2015-05-01 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, J. S.; Hsu, C.; Chiang, N. J.; Tsai, C. S.; Tsou, H. H.; Huang, S. F.; Bai, L. Y.; Chang, I. C.; Shiah, H. S.; Ho, C. L.; Yen, C. J.; Lee, K. D.; Chiu, C. F.; Rau, K. M.; Yu, M. S.; Yang, Y.; Hsieh, R. K.; Chang, J. Y.; Shan, Y. S.; Chao, Y.; Chen, L. T. |
| 國立臺灣大學 |
2015 |
LONG-TERM OUTCOME OF CHEMOTHERAPY-INDUCED HBV REACTIVATION IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION
|
Yang, H. -C.; Tsou, H. -H.; Chuang, M. -H.; Chen, C. -L.; Liu, T. -W.; Chen, P. -J.; Cheng, A. -L.; Hsu, C.; 鄭安理; 許駿; 陳培哲; 陳祈玲 |
| 臺大學術典藏 |
2015 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
on behalf of the Taiwan Cooperative Oncology Group; Wei T.-C.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Chang J.Y.; Yu M.S.; Yang Y.; Hsieh R.K.; Chiu C.F.; Rau K.M.; Lee K.D.; Shiah H.S.; Chang I.C.; Bai L.Y.; Huang S.F.; Tsou H.H.; Tsai C.S.; Chiang N.J.; CHIH-HUNG HSU; Chen J.S.; Chen J.S.;Chih-Hung Hsu;Chiang N.J.;Tsai C.S.;Tsou H.H.;Huang S.F.;Bai L.Y.;Chang I.C.;Shiah H.S.;Ho C.L.;Yen C.J.;Lee K.D.;Chiu C.F.;Rau K.M.;Yu M.S.;Yang Y.;Hsieh R.K.;Chang J.Y.;Shan Y.S.;Chao Y.;Chen L.-T.;Chin Y.-H.;Chung T.-R.;Yu W.-L.;Lee M.-H.;Lin L.-F.;Lin P.-C.;Wu Y.-L.;Wang H.-L.;Lu L.-J.;Chen S.-Y.;Wu C.-C.;Wei T.-C.;On Behalf Of The Taiwan Cooperative Oncology Group; Yen C.J.; Ho C.L. |
| 國立臺灣大學 |
2014 |
PREVENTION OF CHEMOTHERAPY-INDUCED HBV-RELATED HEPATITIS FLARE IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION: COST ANALYSIS
|
Tsou, H. -H.; Yang, H. -C.; Chuang, M. -H.; Wu, H. -Y.; Hsu, Y. -T.; Chang, W. -J.; Hsiao, C. -F.; Hsu, C.; 許駿 |
| 臺大學術典藏 |
2014 |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Wang M.-C.; Lin S.-J.; Tsou H.-H.; Hsu C.; Cheng A.-L.; Liu T.-W.; Chen P.-J.; HWEI-FANG TIEN; Chang C.-S.; Lin J.; Lin S.-F.; Chiu C.-F.; Kao W.-Y.; Yao M.; Hwang W.-L. |
显示项目 51-60 / 64 (共7页)
<< < 1 2 3 4 5 6 7 > >>
每页显示[10|25|50]项目
|
